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Abstract
Background: The costing method used can change the results of economic evaluations. Choosing the appropriate
method to assess the cost of organ recovery is an issue of considerable interest to health economists, hospitals,
financial managers and policy makers in most developed countries.
Objectives: The main objective of this study was to compare a mixed method, combining top-down microcosting
and bottom-up microcosting versus full top-down microcosting to assess the cost of organ recovery in a French
hospital group. The secondary objective was to describe the cost of kidney, liver and pancreas recovery from
French databases using the mixed method.
Methods: The resources consumed for each donor were identified and valued using the proposed mixed method
and compared to the full top-down microcosting approach. Data on kidney, liver and pancreas recovery were
collected from a medico-administrative French database for the years 2010 and 2011. Related cost data were
recovered from the hospital cost accounting system database for 2010 and 2011. Statistical significance was
evaluated at P < 0.05.
Results: All the median costs for organ recovery differ significantly between the two costing methods (non-parametric
test method; P < 0.01). Using the mixed method, the median cost for recovering kidneys was found to be €5155, liver
recovery was €2528 and pancreas recovery was €1911. Using the full top-down microcosting method, median costs
were found to be 21–36% lower than with the mixed method.
Conclusion: The mixed method proposed appears to be a trade-off between feasibility and accuracy for the
identification and valuation of cost components when calculating the cost of organ recovery in comparison to the full
top-down microcosting approach.
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Background
Choosing the appropriate costing method to estimate
accurate costs in healthcare is an issue of considerable
interest to health economists for economic evaluations,
to hospitals for financial management purposes, and to
policy makers in most European countries.
Conventional costing methods are mainly character-
ized by how the two main cost components, i.e., the
process of identification and the process of valuation,
are ordered. Four standard costing methods have been
developed that use microcosting or gross costing for
identification and top-down or bottom-up for valuation
[1]. For cost identification, in microcosting, all cost com-
ponents are defined at the most detailed level, whereas
in gross costing, cost components are defined at a highly
aggregated level. For cost valuation, in the bottom-up
approach, cost components are valued by identifying
resources used directly employed for a patient, whereas
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in the top-down approach, cost components are valued
by separating out the relevant costs from comprehensive
sources. Combining these dimensions gives four theoretic
approaches: top-down gross costing, top-down microcost-
ing, bottom-up gross costing and bottom-up microcost-
ing. Some cost differences are simply due to differences in
costing methodology and reflect different levels of accur-
acy. Previous publications have concluded that the costing
method selected significantly changes the results of eco-
nomic evaluations [2, 3]. Whereas bottom-up microcost-
ing is considered to overestimate assessed costs, top-down
gross costing tends to underestimate them [1].
Regarding healthcare, this methodological aspect is even
more important when cost evaluations cover different
countries. In the past, major variations in hospitals’ cost
accounting systems have been identified across Europe,
making comparisons meaningless [4]. Negrini et al.
highlighted the need for a standardized method for all
European countries to accurately measure the costs of
hospitals’ activities [5]. The introduction of Diagnosis Re-
lated Groups in Europe and the development of activity-
based pricing offered the opportunity, in most European
countries, to develop medico-administrative and economic
databases to analyse hospital activities with a standardized
cost-accounting system [6]. This convergence in the struc-
tural organization of European databases allows compari-
sons in terms of resource consumption between countries
and the development of costing methods that can address
healthcare issues common throughout Europe [7].
The internationalization of health issues is particularly
advanced in the field of organ recovery and organ trans-
plantation [8–10]. Seven European countries rank in the
top 10 countries worldwide in practicing organ recovery
from deceased donors according to the International
Registry in Organ Donation and Transplantation [11].
The improved survival rates obtained with transplantation
and the shortage of available organs have made organ
procurement a vital challenge across Europe [12, 13].
Given the limited resources for healthcare provision,
organ recovery cost data remains paradoxically scarce in
most European countries. In the future, the increasing
number of patients requiring organ transplants in Europe
will make organ recovery cost an international public
health issue [14]. For these reasons, organ recovery
appears to be an interesting topic on which to elaborate
and test an alternative to conventional costing methods.
Bottom-up microcosting is considered to be the best
method to estimate hospital services’ costs, but it is
known to consume resources and time [15]. Drummond
et al. recommended using the bottom-up microcosting
method to evaluate cost components that have a great
impact on total costs [16]. Discussions with the hospital
coordination of organ and tissue procurement allowed
us to elaborate the working hypothesis that consumables
are the most expensive item out of all organ recovery
costs. Instead of conducting a full bottom-up microcost-
ing approach during a multi-step emergency procedure
that compromises real-time acquisition of cost data, we
developed a mixed method combining top-down micro-
costing and bottom-up microcosting to accurately assess
the costs of organ recovery.
Objectives
The main objective of this study was to compare a mixed
method, combining top-down microcosting and bottom-
up microcosting, versus full top-down microcosting to
assess the cost of organ recovery in a French hospital
group. The secondary objective was to describe the cost of
kidney, liver and pancreas recovery from French databases
using the mixed method.
Methods
Study design
The study was implemented in the hospital group the ‘Hos-
pices Civils de Lyon’ (HCL) from January 2010 to December
2011. The HCL acts as a tertiary referral centre for organ re-
covery and organ transplantation. Direct medical costs were
estimated from the hospital’s perspective because organ re-
covery costs come from hospital budgets. Direct non-
medical costs and indirect costs were not considered in this
study. The timeframe considered was from the diagnosis of
brain death until completion of the organ recovery proced-
ure. The costs related to family management, machine per-
fusion and organ shipment were not included because they
are not directly related to the organ recovery procedure.
Registers used
In France, a national hospital discharge database and a hos-
pital cost accounting system were developed. Their use, as a
medico-administrative and an economic database, respect-
ively, allowed for carrying out previous medico-economic
analyses [17]. The French College of Health Economists
recommended using this medico-administrative database for
health economic evaluations [18].
The hospital cost accounting systems implement a na-
tional economic database that groups together representa-
tive hospitals using top-down microcosting [19]. The HCL
group collected cost data during the years 2010 and 2011
through the hospital cost accounting systems. For each dis-
charge abstract collected for each hospital-stay data on med-
ical procedures, all the resources consumed were identified,
quantified and valued using the following methodologies.
Patients and organ collection
All actual brain death donors who underwent kidney, liver
or pancreas recovery in the HCL between 2010 and 2011
were eligible for the analysis. Kidney recovery in this paper
systematically refers to the removal of both kidneys.
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Donors were excluded if cost and/or hospital-stay data
were unavailable. Actual donors were identified in a med-
ical database and selected using the Common Classifica-
tion of Medical Procedures codes corresponding to the
recovery of kidneys, liver and pancreas from donors after
brain death. Living donors and donors after circulatory
death were excluded.
Identification of cost components
The resource identification started from the para-clinical ex-
aminations to determine brain death to the completion of
the organ recovery procedure. The microcosting approach
made it possible to identify, from discharge abstracts and
discussion with hospital coordination of organ and tissue
procurement, seven items divided into 39 sub-items. The
items were surgery, anaesthesia, intensive care, logistics,
biology, imaging and consumables. The sub-items have been
detailed in Additional file 1: Table S1 of the Supplementary
Digital Content (SDC).
Valuation of cost components
All cost components were valued in 2011 Euros. In the
mixed method, surgery, anaesthesia, intensive care, logistic,
imaging and biology were valued using a top-down
approach while consumables were valued using a bottom-
up approach. In the full top-down microcosting method, all
items were valued using a top-down approach (Table 1).
Surgery, anaesthesia and intensive care items were val-
ued from the HCL cost accounting weighted, respectively,
by the surgery Relative Cost Index (RCI), anaesthesia RCI
and a combination of the anaesthesia RCI and length of
stay. The RCI is used to assess the cost of a procedure
carried out in ideal conditions [20]. It is used to break
down the overall cost according to the RCI number
specific to each procedure [21].
Logistics items (sterilization, biomedical engineering,
hygiene and vigilance) were valued from the HCL cost
accounting by isolating components specifically related
to organ recovery.
Biology and imaging exams were valued in the context
of multiple organ recovery. This valuation was based on
the Common Classification of Medical Procedure, No-
menclature of Medical Biology Procedures and the Direc-
tory of establishments receiving global allocation funding
[22]. Biology testing and imaging costs were weighted by
the number of organs recovered from each donor.
For the mixed method analysis, consumables were valued
using a bottom-up approach through the unit purchase
price for the HCL. As the consumables required for kidney
and pancreas recovery are provided in the same surgical
kit, their costs were wholly attributed to kidney procure-
ment or divided between kidney and pancreas procurement
according to which organs were actually recovered (SDC,
Additional file 1: Table S2, Cost of surgical kit for kidney re-
covery in the HCL and Additional file 1: Table S3, Cost of
surgical kit for pancreas recovery in the HCL). As the con-
sumables needed for liver recovery are provided in a separ-
ate surgical kit, the costs were valued using the same
methodology and wholly attributed to liver recovery (SDC,
Additional file 1: Table S4, Cost of surgical kit for liver
recovery in the HCL). The preservation fluid required for
each organ was also valued from the HCL purchase price.
For the full top-down microcosting analysis, consum-
ables were also valued using a top-down method accord-
ing to the HCL cost accounting system.
Outcomes
Comparison of the mixed method versus full top-down
microcosting
The results of the mixed method were compared using the
Wilcoxon signed-rank test for two samples to those obtained
from the full top-down microcosting approach to investigate
possible differences (Table 2). Organ recovery costs were
presented according to their median and interquartile range
(IQR). Statistical significance was evaluated at P < 0.05.
Three cost evaluations of organ recovery were con-
ducted using SPSS Statistics 19. Each explores a specific
characteristic of organ recovery procedures.
1) The cost of separate kidney, liver and pancreas
recovery regardless of the organs actually recovered
to obtain the cost for each organ recovered with a
view to future medico-economic studies.
2) The cost of the most common organ recovery
procedures: kidneys alone, kidneys and liver, kidneys,
liver and pancreas to better reflect the realities of
organ recovery.
3) The cost of kidney recovery according to the
number of organs recovered to highlight a possible
economy of scale when several organs are recovered
simultaneously.
Table 1 Identification and valuation modalities of the seven













eCommon Classification of Medical Procedure
fNomenclature of Medical Biology Procedures
gNegotiated Price for HCL in 2011
Hrifach et al. Health Economics Review  (2016) 6:53 Page 3 of 7
Analysis of organ recovery costs calculated by mixed
method
The relative proportion of expenditure items was also
specified for separate kidney, liver and pancreas recovery
to test the initial hypothesis regarding the high propor-
tion of consumable costs with regard to the total cost
(Table 3). Moreover, we analysed the cost of kidney re-
covery according to the number of recovered organs to
highlight potential economies of scale.
Results
93 actual brain death donors underwent kidney, liver or
pancreas recovery in the HCL. 2 donors, corresponding
to 2 pairs of kidneys, were excluded due to missing cost
data. A total of 91 actual brain death donors were in-
cluded in the analysis corresponding to a total of 83
pairs of kidneys, 63 livers and 25 pancreases. The organs
recovered but not analysed were lungs, heart and intes-
tines (SDC, Additional file 1: Table S5, Organs recovered
in the HCL from January 2010 to December 2011).
Comparison of the mixed method versus full top-down
microcosting
The cost of organ recovery assessed using the mixed
method differs significantly from the cost obtained using
the full top-down microcosting approach (Wilcoxon
signed-rank test for two samples; P < 0.01).
Using the mixed method, the median cost for kidneys,
livers and pancreases was assessed as €5155 (IQR €913),
€2528 (IQR €447) and €1911 (IQR €208), respectively.
The cost of the following combinations: kidneys alone;
kidneys and liver; and kidneys, liver and pancreas was
assessed at €5439 (IQR € 710), €8060 (IQR €944) and
€8562 (IQR €766), respectively.
Using the full top-down microcosting approach, the
median cost fell by 21–36% compared to the mixed cost-
ing method, and the interquartile range increased con-
siderably. Thus, the median costs for kidneys, livers and
pancreases were assessed as €3283 (IQR €1428), €1826
(IQR €1138) and €1505 (IQR €322), respectively. The
cost of the following combinations: kidneys alone; kid-
neys and liver; and kidneys, liver and pancreas was
assessed at €3811 (IQR €2139), €5830 (IQR €2665) and
€5822 (IQR €1225), respectively. In comparison with the
mixed method, the median costs are lower using the full
top-down method and the interquartile ranges are wider.
Analysis of organ recovery costs calculated by mixed
method
The mean costs assessed by the mixed method for re-
covery of kidneys, liver and pancreas in the HCL showed
that the consumables were the largest item in terms of
value and proportion regardless of the organ analysed
(Table 3). They accounted for almost half of the total
Table 2 Mixed method versus full top-down microcosting to assess organ recovery cost in HCL (2011 Euros)
Mixed Method Full Top-down Microcosting
Organ(s) Organ(s) N Median IQR Median IQR P* ΔMedian (%)
1stevaluation
Kidneys 83 5,155 913 3,283 1,428 ˂0,0001 −36,32
Liver 63 2,528 447 1,826 1,138 ˂0,0001 −27,78
Pancreas 25 1,911 208 1,505 322 0,0127 −21,26
2ndevaluation
Kidneys alone 21 5,439 710 3,811 2,139 0,0001 −29,93
Kidneys + Liver 27 8,060 944 5,830 2,665 ˂0,0001 −27,66
Kidneys + Liver + Pancreas 23 8,562 766 5,822 1,225 ˂0,0001 −32,00
3rdevaluation
Kidneys alone 21 5,439 710 3,811 2,139 0,0001 −29,93
Kidneys + 1 other organ 29 5,436 677 3,639 1,229 ˂0,0001 −33,06
Kidneys + 2 or more other organs 33 4,551 631 2,910 528 ˂0,0001 −36,05
p*: Wilcoxon signed-rank test
Table 3 Breakdown of mean cost assessed by mixed method for the recovery of kidneys, liver and pancreas in the HCL (2011 Euros)
Cost Euros (%)
ORGAN Surgery Anaesthesia Intensive Care Logistics Imaging Biology Consumables Total
Kidneys 750 (15%) 676 (13%) 697 (13%) 95 (2%) 202 (4%) 359 (7%) 2,356 (46%) 5,135 (100%)
Liver 227 (9%) 284 (11%) 318 (13%) 51 (2%) 162 (6%) 287 (11%) 1,244 (48%) 2,574 (100%)
Pancreas 224 (12%) 283 (15%) 194 (10%) 40 (2%) 105 (5%) 187 (10%) 894 (46%) 1,928 (100%)
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cost. Out of the different consumables, the preservation
fluid was the most expensive item (€364 for 2 l) (SDC,
Additional file 1: Table S2, Cost of surgical kit for kidney
recovery in the HCL). Surgery, anaesthesia and intensive
care items represented approximately one-third of the
total cost in each case. The remaining cost, between 13
and 19%, included logistics, imaging and biological test-
ing (Table 3).
Moreover, the cost of kidney recovery according to the
number of recovered organs was assessed at €4551 (IQR
€631) (N = 33) and €5439 (IQR € 710) (N = 21) in the
HCL (Table 2). This cost gradually decreased as the
number of organs recovered increased. Surgery, anaes-
thesia, intensive care and logistics have approximately
constant values. The cost reduction was related to the
gradual decrease in the cost of consumables, imaging
and biological testing due to economies of scale.
Discussion
The mixed method makes it possible to assess organ recov-
ery cost from French databases and appears to combine the
accuracy of the bottom-up method and the simplicity of
the top-down approach. The costs of organ recovery
assessed using the mixed method differ significantly from
those assessed using the full top-down microcosting ap-
proach. The full top-down microcosting approach resulted
in a 21–36% lower median cost and carried the risk of
underestimating assessed costs in comparison to the mixed
method. There are several explanations for the differences
between the two methods. The full top-down method gives
all items identified the same degree of accuracy regardless
of the importance of the different cost components in
terms of value and proportion. Although consumables
represent the largest part of the cost of organ recovery, the
full top-down method cannot include all consumables
because they are not adequately tracked at the patient level.
The fact that consumables represent 46% of the total cost
confirms the working hypothesis to use a bottom-up strat-
egy to value this item.
The validation of the proposed methodology through
the comparison of our results to national and inter-
national cost data cannot be carried out because the
available cost data are scarce and old. Currently, few
European countries have examined organ recovery costs
from a hospital perspective. Lenisa et al. assessed the
cost of kidney and pancreas procurement at $1400 in
the Italian healthcare system [23]. A single publication
assessed the cost of pancreas procurement in the French
system at €1086 [24]. In Spain, a cost-benefit estimation
found kidney procurement to be $3162 [25]. Although
tariffs are different from costs, being unable to compare
our results to recent costs, we compared the results of
this analysis to the French tariffs. The specific tariffs
(PO1 to PO4) established for hospital remuneration for
organ recovery activities in the French healthcare system
are closer to the estimates made with the mixed method
than the estimates made with the full top-down method
[26]. Under the 2011-PO3 tariff (€8473), the fee for sim-
ultaneous kidney, liver and pancreas recovery is closer to
the estimate made through the mixed method (€8562)
than the estimate made with the full top-down method
(€6180). This information seems to indicate a better esti-
mation of organ recovery valuation with the mixed
method in comparison to the full top-down approach.
Some limitations of our work should be noted. From a
methodological point of view, the valuation of the surgery
and anaesthesia items needs to be improved. Both items
were assessed using relative cost index, which does not re-
flect the actual time spent by surgeons and anaesthetists on
the procedure. Therefore, neither the full top-down method
nor the proposed mixed method accurately measures these
variables. As suggested by Mercier et al., the introduction
of time-driven activity-based costing will provide a more
accurate weighting, with minimal adjustment, while offset-
ting the non-consideration of operation time variation in
top-down methods [27]. Moreover, considering indirect
costs, such as overhead and capital, would contribute to a
more comprehensive cost estimation for hospital services
[28]. Although the hospitals participating in the national
economic database use a common top-down microcosting
procedure for calculating costs, some variations in the
practical implementation were observed that cannot be
analysed from a single hospital group. Extending the pro-
posed mixed methodology to a larger number of European
hospitals would offer methodological and financial results.
Cost data from a limited number of hospitals in several
countries would be preferable to analysing a large number
of hospitals in one country [29].
Extrapolation of the mixed method to other countries
requires the availability of both a cost accounting system
and a medico-administrative database. Moreover, only
countries using a top-down microcosting approach for
direct cost allocation such as Germany, England and
Estonia will allow the implementation of the mixed
method proposed in the French context [4]. The mixed
method appears to be difficult to extrapolate to countries
using a full bottom-up costing approach such as Finland,
the Netherlands and Sweden [4]. However, it would be
interesting to compare the results of the mixed method
with those of countries using a full bottom-up method.
Effectively, comparisons of the value and the proportion
of the seven items identified for organ recovery would
indicate if the mixed method provides sufficient accuracy
when compared to the full bottom-up method. According
to Geissler et al., Ireland, Portugal and Spain have low-
quality patient-level cost information [6]. Extrapolating
the mixed method to these countries would also be inter-
esting. The use of a mixed methodology seems to be
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effective when conducting cost studies in countries with
limited or low-quality data [30].
Conclusions
Through the procedure of organ recovery, this study high-
lights the necessary trade-off between top-down simplicity
and bottom-up accuracy to obtain valid cost estimates to
meet the increased demand for medico-economic data. It
would be interesting to test the mixed method on other
medical procedures. The proposed method could be used
whenever a potentially expensive technological innovation
is introduced into a previously well valued procedure in
order to focus the valuation efforts on the unknown por-
tion of the cost. In the same way, the mixed method could
also be used for a not yet valued procedure when a cost
component is known to represent a large part of a total
cost. In all these situations, the mixed method can provide
feasibility, rapidity and accuracy.
Supplementary data
Supplementary data are available online.
Key-points
 The mixed method appears to be a trade-off be-
tween the accuracy of the bottom-up approach and
the simplicity of the top-down approach.
 The cost of organ recovery assessed using the mixed
method differs significantly from the cost obtained
using the full top-down microcosting approach.
 The use of a full top-down microcosting method
carries the risk of underestimating assessed costs in
comparison to the mixed method.
 Extrapolation of the mixed method to other
countries requires the availability of both a cost
accounting system and a medico-administrative
database.
 The mixed method could be used whenever an
expensive technological innovation is introduced
into a previously well valued procedure or for a not
yet valued procedure when a cost component is
known to represent a large part of a total cost.
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